Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)

NCT02971007 is registered in ClinicalTrials.gov with Matinas BioPharma Nanotechnologies, Inc. as lead sponsor.

NCT NCT02971007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02971007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2016
Completion date
May 31, 2017
Enrollment
137 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

candidiasis, vulvovaginal, vulvovaginitis, yeast infection, yeast infection vaginal